Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced Preston S. Klassen, M.D., President and Head of Research & Development, has been appointed to the Company’s Board of Directors.
“We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD,” said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus. “His expertise in nephrology, along with his previous leadership and board experience in the industry, will make him an invaluable member, and we look forward to his contributions to Regulus and our science.”
Preston S Klassen MD recently joined Regulus Therapeutics as President and Head of Research and Development. Dr. Klassen is a nephrologist by training who brings over 20 years of experience in pharmaceuticals, including positions in leadership, medical affairs, and research and development across multiple therapeutic areas. Most recently he served as the President and CEO of Metacrine. Prior to that, he was an Executive Vice President and Head of R&D at Arena Pharmaceuticals, CMO and President at SANIFIT, and Senior Vice President and Head of Global Development at Orexigen Therapeutics. Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology. Dr. Klassen earned his M.D. from the University of Nebraska Medical Center and completed both his residency in internal medicine and fellowship in nephrology as well as his Master’s in Health Sciences at Duke University Medical Center.
